Impact of a Skin Model on the In Vitro Performance of a Zolmitriptan-Coated Adhesive Dermally Applied Microarray

• P Bhagath

  English

  Author

• M Pullagura

  English

  Author

For the investigation of percutaneous absorption and the assessment of the pharmacokinetics of
medications administered topically, the Franz in vitro human skin finite dose model has proven to be an
invaluable resource. The model makes use of ex vivo human skin that is mounted in specially made
diffusion cells, which enable the skin to be kept at a temperature and humidity that are similar to those
found in vivo [1]. A limited amount of a formulation (for instance, 2–10 mg/cm2 of a semisolid or
transdermal delivery system) is applied to the skin's outer layer and the pace at which the medication
appears in the receptor solution that bathes the inner surface of the skin is used to quantify drug absorption.
This model allows for the determination of data specifying skin content, absorption rate, and total
absorption. The technique has a long history of correctly forecasting the kinetics of percutaneous absorption
in vivo [2, 3]. Using ex vivo skin of different thicknesses as the diffusional barrier, the Franz cell has also
been used to evaluate microneedle-mediated drug delivery [4–6]. Another potential substitute for ex vivo
skin has been proposed: synthetic membranes like Silescol® [7, 8]. The alleged benefits of using synthetic
membranes' accessibility, usability, and storage simplicity, as well as their potential to reduce the
unpredictability related to the usage of ex vivo skin [9]. Unambiguous correlation to human stratum
corneum barrier function has not yet been thoroughly investigated, especially for finite dose applications,
despite the potential benefits of artificial membranes over human skin [10].

• pdf